Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 7:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Subcutaneous Adipose Tissue Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women

NCT01127867
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
dietary intervention
Dietary Supplement
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 17, 2026, 7:42 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

NCT07526974
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
11
States / cities
Encinitas, California • Aventura, Florida • Alpharetta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 17, 2026, 7:42 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Microvascular Flow Assessment Repeatability Study: The MARS Study

NCT01242020
View directory record Official record
Conditions
Obesity
Interventions
Perflutren Lipid Microsphere Injectable Suspension
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System

NCT07122583
View directory record Official record
Conditions
Non-Surgical Fat Reduction
Interventions
CoolSculpting Elite System
Device
Lead sponsor
AbbVie
Industry
Eligibility
22 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

NCT02163902
View directory record Official record
Conditions
Submental Fat, Healthy
Interventions
ATX-101, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
13
States / cities
San Diego, California • Englewood, Colorado • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 17, 2026, 7:42 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

NCT07140939
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug · Other
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
11
States / cities
Encinitas, California • West Palm Beach, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci

NCT01519492
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Wound Infection, Cutaneous Abscess, Burn Infection, Cellulitis
Interventions
AFN-12520000
Drug
Lead sponsor
Affinium Pharmaceuticals, Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Buena Park, California • Chula Vista, California • La Mesa, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

NCT00918606
View directory record Official record
Conditions
Subcutaneous Adipose Tissue Reduction
Interventions
LIPO-102
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 17, 2026, 7:42 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride

NCT06820164
View directory record Official record
Conditions
Lipoma
Interventions
Cooled Sodium Chloride Injection, Warmed Sodium Chloride Injection
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment Method

NCT01853397
View directory record Official record
Conditions
Subcutaneous Adipose Tissue
Interventions
Liposonix System (Model 2)
Device
Lead sponsor
Solta Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Hayward, California • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

NCT06005441
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 injection, CBL-A1 Injection, CBL-A2 Injection, 0.9% Sodium Chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 17, 2026, 7:42 AM EDT
Completed No phase listed Observational

Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections

NCT02060513
View directory record Official record
Conditions
Infection, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
Interventions
Not listed
Lead sponsor
Connie Price
Other
Eligibility
18 Years and older
Enrollment
2,298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Denver, Colorado • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

NCT03005717
View directory record Official record
Conditions
Submental Fat
Interventions
LIPO-202, Placebo for LIPO-202
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Beverly Hills, California • Manhattan Beach, California • Greenwood Village, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Subcutaneous Fat Reduction in the Submental Area

NCT02298322
View directory record Official record
Conditions
Body Fat Disorder
Interventions
CoolSculpting System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
22 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Sacramento, California • Edina, Minnesota • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01426373
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
18
States / cities
Beverly Hills, California • La Jolla, California • San Juan Capistrano, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

rPMS and Radiofrequency for Abdominal Toning and Reduction of Subcutaneous Fat

NCT04587986
View directory record Official record
Conditions
Fat Burn
Interventions
BTL-899
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
River Bluff, Kentucky • Hunt Valley, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01542034
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
506 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 17, 2026, 7:42 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

NCT07220785
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
Mibavademab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Not applicable Interventional Results available

STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

NCT02503852
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Puregraft System, Celution System, Kerastem Therapy, Liposuction
Device · Procedure
Lead sponsor
Kerastem Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Highland Park, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 17, 2026, 7:42 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)

NCT02115724
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Antioxidant cocktail, Biopsy, Placebo, NMD; 0.4mg sub-lingual nitroglycerin spray
Dietary Supplement · Other · Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 40 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 17, 2026, 7:42 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

ADRB3 Signaling Pathway in Human Adipose Tissue

NCT05634174
View directory record Official record
Conditions
Obesity, Prediabetes
Interventions
Mirabegron
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 17, 2026, 7:42 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Aerobic and Resistance Training on Abdominal Fat Loss

NCT03700827
View directory record Official record
Conditions
Obesity, Abdominal
Interventions
Resistance Training, Aerobic Training
Other
Lead sponsor
Southern Illinois University Edwardsville
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Edwardsville, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Not applicable Interventional

Use of MCT Oil for Enhancement of Weight Loss in Obese Patients

NCT00207272
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
1170-1870 kcal/day liquid diet, Gastric bypass surgery, Biopsy.visceral adipose tissue, Biopsy.omental adipose tissue, Biopsy. subcutaneous abdominal adipose tissue, Blood sample
Behavioral · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2008 · Synced Sep 17, 2026, 7:42 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

NCT07733947
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9 % sodium chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 17, 2026, 7:42 AM EDT